Sweden approves generic copy of GSK's top lung drug
LONDON Jan 14 (Reuters) - Sweden has followed Denmark and Germany in approving the sale of a generic copy of GlaxoSmithKline's $8 billion-a-year inhaled lung drug Advair.
Britain's Vectura said on Tuesday its partner Sandoz, the generics division of Switzerland's Novartis , had received Swedish authorisation for its generic version of the drug, known as AirFluSal Forspiro.
The initial Danish green light was given to the product in December.
- French warplanes search Mali desert for crashed Air Algerie plane |
- At least 15 killed by shelling of Gaza school; toll exceeds 760 |
- Exclusive: Ukraine rebel commander acknowledges fighters had BUK missile
- U.S. House panel votes to authorize lawsuit against Obama
- Lawyers call for outside probe of 'bungled' Arizona execution |